AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04482686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hcl
Description: 10 day treatment
Study NCT04482686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 10 Day treatment
Study NCT04482686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: 10 Day treatment
Study NCT04482686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 10 day treatment
Study NCT04482686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 10 day treatment
Study NCT04482686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 10 day treatment
Study NCT03879772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray
Description: intranasal administration
Study NCT04482686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: 10 day treatment
Study NCT00434005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, ascorbate
Description: NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
Study NCT00434005 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: N-acetylcysteine, ascorbate
Description: NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
Study NCT00434005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matched appearance to acetylcysteine and ascorbate intervention
Study NCT00434005 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: matched appearance to acetylcysteine and ascorbate intervention
Study NCT04020627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiPAP Group
Description: BIPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device
Study NCT04020627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP Group
Description: CPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device
Study NCT03266705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: bioequivalence study
Study NCT03051243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin and Basal Insulin
Description: Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals
Study NCT03051243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin and Bolus Insulin
Description: Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
Study NCT03787927 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Autologous Platelet Transfusion (room-temperature-stored)
Description: The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Study NCT03787927 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Autologous Platelet Transfusion (cold-stored 5 days)
Description: The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
Study NCT03787927 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Autologous Platelet Transfusion (cold-stored 10 days)
Description: The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
Study NCT03787927 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Autologous Platelet Transfusion (cold-stored 15 days)
Description: The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
Study NCT03787927 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Aspirin (325mg) will be administered the day before every transfusion.
Study NCT03787927 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel (600mg) will be administered the day before every transfusion.
Study NCT00737373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2 qd15
Study NCT00737373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600mg/m2 qd15
Study NCT00737373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 2600mg/m2 qd15
Study NCT00737373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 qd15
Study NCT00737373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m2 qd15
Study NCT00737373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: 200mg/m2 qd15
Study NCT00737373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid
Description: 200mg/m2 qd15
Study NCT03879772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: intranasal administration
Study NCT03879772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: intranasal administration
Study NCT03879772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpheniramine maleate syrup
Description: oral administration
Study NCT03879772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate syrup
Description: oral administration
Study NCT03879772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorpheniramine maleate syrup
Description: oral administration
Study NCT02254070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBT 986 BS
Study NCT00912808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil, 5 mg, capsule, once a day, 3 weeks
Study NCT00912808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (placebo)
Description: sugar pill, one capsule, once a day, 3 weeks
Study NCT00157131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant, ARTISS 4IU/ml VH SD
Description: FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
Study NCT00157131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Administration by mechanical/multiple point fixation.
Study NCT00598338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study NCT00598338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study NCT05104138 — intervention group
Intervention type: DRUG
Intervention: Eplerenone
Description: The patients underwent eplerenone treatment for 6 months
Study NCT05104138 — intervention group
Intervention type: DEVICE
Intervention: The patients underwent half fluence photodynamic therapy for 6 months
Description: Half fluence photodynamic therapy for 6 months
Study NCT03817216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatic Urethral Lift (PUL)
Description: PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
Study NCT03817216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Urethral Lift (PUL)
Description: PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
Study NCT01502826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: standardized mixed meal
Description: All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
Study NCT06522646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPCM
Description: During a period of 4-6 weeks, patients will live in their usual environment with the SPCM prosthesis
Study NCT06522646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Prothesis
Description: During a period of 4-6 weeks, patients will live in their usual environment with their usual microprocessor prosthesis
Study NCT02878031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin for CI pneumonia
Description: CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age \<12 months (4 - \<10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age \<3 years (10 kg - \<14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children \<5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.
Study NCT02396576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
Study NCT01961037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi: Moving for Better Balance
Description: Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
Study NCT02322632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol Capsules, 4 mcg
Description: Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
Study NCT01995838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Description: E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
Study NCT01995838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
Study NCT03415685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PicoPlus laser system
Description: Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
Study NCT03836313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera°
Description: Cryoneurolysis treatment using the iovera° device targeting the anterior femoral cutaneous nerve (AFCN) and the infrapatellar branch of the saphenous nerve (ISN) will occur approximately 4 weeks before surgery by a trained member of the study staff. Treatment will occur in clinic using suggested anatomical markings to target appropriate the AFCN and infrapatellar branch of the saphenous nerve (ISN) of the operative knee.~The iovera° device contains three 27- gauge needles, all 6.9mm in length which will indent the subjects' skin and be inserted under the subcutaneous fat about 7 mm. Lidocaine will be used for superficial anesthetic at the treatment site before the needles puncture the patient's skin.There are a total of 9 iovera° cooling cycles. Treatment will be performed unilaterally and will be guided by visualization and palpation of anatomical landmarks.
Study NCT02512783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
Study NCT02512783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
Study NCT02512783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous administration of propofol according to standard care to sedate patient.
Study NCT02512783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Intravenous administration of propofol according to standard care to sedate patient.
Study NCT04532528 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran
Study NCT01023763 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A structured training program
Description: A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
Study NCT00212108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib, gefitinib
Description: The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
Study NCT03987269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Embodied Virtual Reality
Description: The video will be formatted for viewing within a standard virtual reality headset. Once the video begins, subjects will follow the movements of the new body they are inhabiting in synchronicity to the video. Movement and haptic input include~1. Mimicking the hand gestures at the beginning in order to establish the body transfer illusion.~2. Shaking someone's hand~3. Someone holding the hand and elbow to assist them in standing, taking a few steps and returning to a seated position.~4. Shaking hands~5. Having their blood pressure taken~6. Having their pulse taken~7. Fill a pill organizer~8. Color a picture~All of the above interactions will be facilitated by the two Co-PI's (Blatter, Ware). Blatter and Ware have been creating and performing similar Virtual Reality Embodiments with haptics for the past year, and to date, have performed hundreds of them for demos, colleagues, students and the public.
Study NCT03987269 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Narrative Video
Description: The video will be formatted for a standard flat screen television. Participants will watch the video alone in a standard School of the Arts classroom.
Study NCT03725397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient
Description: The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.
Study NCT03725397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient
Description: Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care.
Study NCT01152632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: manual acupuncture
Description: thirty minutes duration every time, five times per week for one course, a total four courses
Study NCT01152632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual acupuncture
Description: thirty minutes duration every time, five times per week for one course, a total four courses
Study NCT03518853 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course Hypofractionated Once-weekly Radiation Therapy
Description: Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
Study NCT02940795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coke
Description: Patients were given a 20 ounce bottle of Coke Cola.
Study NCT02940795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Rite
Description: Patients were given a 12 ounce can of Diet Rite.
Study NCT00517387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
Study NCT04218526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise DBS System
Description: Vercise Deep Brain Stimulation (DBS) System that consists of two bilateral directional DBS Cartesia electrodes implanted in the cuneiform nucleus and a Gevia generator implanted in the upper chest area just below the clavicle.
Study NCT02870595 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microvibratory Stimulator
Description: Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
Study NCT02870595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microvibratory Stimulator
Description: Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
Study NCT02870595 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microvibratory Stimulator'
Description: As above, Microvibratory Stimulator will be used as a sham device in parallel group.
Study NCT02870595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microvibratory Stimulator'
Description: As above, Microvibratory Stimulator will be used as a sham device in parallel group.
Study NCT04170608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FARAPULSE Endocardial Multi Ablation System
Description: Ablation using the FARAPULSE Endocardial Multi Ablation System
Study NCT02080715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: 2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
Study NCT02080715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01161277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Dose: 5-10 mg depending on subject weight
Study NCT01161277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Dose: 1-2 mg depending on subject weight
Study NCT01161277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sugar pill
Description: Dose: 1-2 pills depending on subject weight
Study NCT04565132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Definition transcranial Direct Current Stimulation
Description: 1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
Study NCT03631251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Placebo
Description: Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
Study NCT02307825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: The drug will be taken three times a week for four months.
Study NCT02307825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be taken three times a week for four months.
Study NCT02383576 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention administered in this study.
Study NCT01152632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual acupuncture
Description: thirty minutes duration every time, five times per week for one course, a total four courses
Study NCT01630746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Study NCT04147078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine subcutaneous administration
Description: subcutaneous administration
Study NCT01182701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral training
Description: The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program